TargetMol

KRH-3955 Salt

Product Code:
 
TAR-T27742
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27742-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
KRH-3955, a CXCR4 antagonist, is an orally bioavailable and extremely potent inhibitor of HIV-1 infection.
CAS:
1097732-62-1
Formula:
C40H63N7O18
Molecular Weight:
929.975
Purity:
0.98
SMILES:
O[C@H]([C@@H](O)C(O)=O)C(O)=O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCCN(CCC)CCCCN(C)Cc1ccc(CN(Cc2ncc[nH]2)Cc2nccn2C)cc1

References

1. Hikichi Y, Yokoyama M, Takemura T, Fujino M, Kumakura S, Maeda Y, Yamamoto N, Sato H, Matano T, Murakami T. Increased HIV-1 sensitivity to neutralizing antibodies by mutations in the Env V3-coding region for resistance to CXCR4 antagonists. J Gen Virol. 2016 Jul 1. doi: 10.1099/jgv.0.000536. [Epub ahead of print] PubMed PMID: 27368421. 2. Iwanaga T, Iwasaki Y, Ohashi M, Ohinata R, Takahashi K, Yamaguchi T, Matsumoto H, Nakano D. [Inhibitory effect of CXCR4 blockers on a CXCR4-expressing gastric cancer cell line in nude mice]. Gan To Kagaku Ryoho. 2012 Nov;39(12):1788-90. Japanese. PubMed PMID: 23267887. 3. Nakasone T, Kumakura S, Yamamoto M, Murakami T, Yamamoto N. Single oral administration of the novel CXCR4 antagonist, KRH-3955, induces an efficient and long-lasting increase of white blood cell count in normal macaques, and prevents CD4 depletion in SHIV-infected macaques: a preliminary study. Med Microbiol Immunol. 2013 Apr;202(2):175-82. doi: 10.1007/s00430-012-0254-1. Epub 2012 Jul 8. PubMed PMID: 22772800. 4. De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil?) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther. 2010 Dec;128(3):509-18. doi: 10.1016/j.pharmthera.2010.08.009. Epub 2010 Sep 15. Review. PubMed PMID: 20826182.